NYSE:JNJPharmaceuticals
Will Late-Stage Immunology and Oncology Wins Redefine Johnson & Johnson's (JNJ) Post-Biosimilar Narrative?
In early June 2026, Johnson & Johnson reported a series of positive late-stage data readouts and regulatory advances across its immunology and oncology pipeline, including Phase 2 nipocalimab results in lupus and Sjögren’s disease, strong MajesTEC-9 outcomes for TECVAYLI in multiple myeloma, and an FDA label expansion for TREMFYA in psoriatic arthritis.
These outcomes highlight Johnson & Johnson’s broad, late-stage innovation across autoimmune and cancer indications, reinforcing its efforts...